To clarify the actual administration of thiamazole (MMI), the first choice of antithyroid drugs, the actual therapy provided by the Japan Thyroid Association (JTA) members for the following conditions was surveyed. The subjects included adult patients, pregnant women, and pediatric patients with Graves’ disease who visited each medical institution from September 2019 to February 2020. Initial doses, frequency of administration, maintenance doses, maximum doses, consultation intervals for pregnant women, and dosages administrated to breastfeeding mothers were surveyed. The total number of cases collected was 11,663. Administration of 15 mg once a day was the most common initial therapy, constituted 74.4% (2,526/3,397 cases) of adults, 33.8% (44/130) of pregnant women, and 50.8% (61/120) of children. The maintenance dose before discontinuation was equivalent to 2.5 mg/day in 52.3% (3,147/6,015). The most common maximum dose for adults and children was 30 mg/day, administrated to 57.5% of adults (223/388) and 59.6% (28/47) of children; for pregnant women, it was 15 mg/day, administrated to 71.1% (27/38). The most common consultation interval for pregnant women was every four weeks (32.1%, 341/1,063). In lactating mothers, the dose was 10 mg/day or less in 366 of 465 cases (78.7%). Breastfeeding was also allowed 4–6 hours after the administration of 15–20 mg/day in 69 patients (14.8%). Breastfeeding was prohibited in 26 patients (5.6%). In conclusion, initial MMI therapy was started with 15 mg once a day in most patients, and MMI was also administrated to lactating mothers following the Graves’ disease treatment guidelines by the JTA.

为明确抗甲状腺药物首选噻唑唑（MMI）的实际给药情况，对日本甲状腺协会（JTA）成员针对以下情况提供的实际治疗进行了调查。受试者包括 2019 年 9 月至 2020 年 2 月在各医疗机构就诊的成年患者、孕妇和儿童患者。初始剂量、给药频率、维持剂量、最大剂量、孕妇咨询间隔和给药剂量对母乳喂养的母亲进行了调查。收集的案件总数为11,663。每天一次 15 mg 的给药是最常见的初始治疗，占成人的 74.4%（2,526/3,397 例）、孕妇的 33.8%（44/130）和儿童的 50.8%（61/120）。在 52.3% (3,147/6,015) 中，停药前的维持剂量相当于 2.5 mg/天。成人和儿童最常见的最大剂量为 30 毫克/天，57.5% 的成人 (223/388) 和 59.6% (28/47) 的儿童服用；孕妇每日15mg，给药率为71.1%（27/38）。孕妇最常见的咨询间隔是每 4 周一次 (32.1%, 341/1,063)。在哺乳期母亲中，465 例中有 366 例（78.7%）的剂量为 10 毫克/天或更少。69 名患者（14.8%）每天服用 15-20 毫克后 4-6 小时也允许母乳喂养。26 名患者（5.6%）禁止母乳喂养。总之，在大多数患者中，初始 MMI 治疗以每天 15 mg 开始，并且还按照 JTA 的 Graves 病治疗指南对哺乳期母亲进行 MMI。